TG Therapeutics, Inc. (TGTX)
Company Info
Highlights
$5.45B
$0.25
137.44
$386.39M
$337.73M
$66.40M
$15.16 - $46.48
$41.20
19.04%
8.05
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
TG Therapeutics, Inc. (TGTX) returned 14.15% year-to-date (YTD) and 108.50% over the past 12 months. Over the past 10 years, TGTX returned 7.97% annually, underperforming the S&P 500 benchmark at 10.87%.
TGTX
14.15%
-10.33%
16.32%
108.50%
12.87%
7.97%
^GSPC (Benchmark)
1.30%
12.79%
1.49%
12.35%
15.37%
10.87%
Monthly Returns
The table below presents the monthly returns of TGTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5.32% | -5.08% | 31.04% | 15.42% | -24.50% | 14.15% | |||||||
| 2024 | -4.92% | 6.03% | -11.67% | -10.19% | 19.33% | 9.14% | 11.07% | 18.88% | -0.43% | 7.14% | 38.87% | -13.51% | 76.23% |
| 2023 | 28.74% | 5.19% | -6.12% | 65.09% | 7.25% | -6.72% | -16.71% | -49.40% | -20.15% | -7.54% | 65.72% | 33.33% | 44.38% |
| 2022 | -39.11% | -14.69% | -3.65% | -27.02% | -36.31% | -3.85% | 40.94% | 19.03% | -16.97% | -1.69% | 51.55% | 34.13% | -37.74% |
| 2021 | -7.21% | -9.32% | 10.12% | -7.24% | -22.01% | 11.24% | -9.80% | -22.64% | 22.94% | -6.19% | -51.31% | 25.00% | -63.48% |
| 2020 | 28.02% | -11.68% | -21.59% | 19.51% | 58.59% | 4.45% | 0.51% | 26.69% | 7.88% | -5.57% | 16.11% | 77.30% | 368.65% |
| 2019 | 0.00% | 65.85% | 18.24% | -1.12% | -21.13% | 37.96% | -13.41% | -17.09% | -9.58% | 21.64% | 19.91% | 35.53% | 170.73% |
| 2018 | 40.24% | 21.74% | 1.43% | 1.06% | -6.62% | -1.87% | -10.65% | 8.09% | -55.91% | -18.75% | 10.77% | -18.65% | -50.00% |
| 2017 | 3.23% | 18.75% | 104.39% | -5.15% | 1.81% | -10.67% | 14.43% | 10.43% | -6.69% | -31.22% | 5.52% | -4.65% | 76.34% |
| 2016 | -31.52% | 1.96% | 2.28% | 6.92% | -17.45% | -19.41% | -2.48% | 7.45% | 21.89% | -30.88% | 7.48% | -19.13% | -61.02% |
| 2015 | -10.10% | 1.90% | 6.69% | -9.82% | 12.75% | 5.40% | 5.18% | -29.63% | -17.92% | 22.72% | 6.55% | -9.48% | -24.68% |
| 2014 | 53.85% | 10.00% | 4.55% | -22.75% | 22.51% | 43.80% | -15.76% | 7.21% | 25.83% | 3.00% | 35.76% | 6.17% | 306.15% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 88, TGTX is among the top 12% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for TG Therapeutics, Inc. (TGTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the TG Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the TG Therapeutics, Inc. was 100.00%, occurring on Dec 29, 2011. The portfolio has not yet recovered.
The current TG Therapeutics, Inc. drawdown is 99.98%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -100% | Oct 23, 1997 | 3241 | Dec 29, 2011 | — | — | — |
| -51.9% | Feb 29, 1996 | 244 | Apr 11, 1997 | 110 | Oct 13, 1997 | 354 |
| -13.7% | Feb 9, 1996 | 7 | Feb 20, 1996 | 2 | Feb 22, 1996 | 9 |
| -13.21% | Jan 15, 1996 | 3 | Jan 17, 1996 | 12 | Feb 2, 1996 | 15 |
| -10.2% | Dec 29, 1995 | 1 | Dec 29, 1995 | 6 | Jan 10, 1996 | 7 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of TG Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of TG Therapeutics, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -82.8%.
Valuation
The Valuation section provides an overview of how TG Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for TGTX, comparing it with other companies in the Biotechnology industry. Currently, TGTX has a P/E ratio of 137.4. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for TGTX compared to other companies in the Biotechnology industry. TGTX currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TGTX relative to other companies in the Biotechnology industry. Currently, TGTX has a P/S ratio of 14.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TGTX in comparison with other companies in the Biotechnology industry. Currently, TGTX has a P/B value of 23.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |